With our solutions, AlpVision is actively contributing to solving the counterfeiting problem that has occurred with COVID-19-related pharmaceutical products. Last year, we launched the COVID-19 Initiative, offering special conditions for protecting against any counterfeit drugs related to COVID-19. This offer was really successful, and two pharmaceutical companies decided to use our technologies:
- One deployment was completed on packaging using our Cryptoglyph technology.
- A second deployment is ongoing. This one uses our Fingerprint technology.
Obviously, customers needed ultrafast implementation, and we were very proud to have succeeded in both the cases above.
In parallel, we replied to a consultation of the EU, which wanted to assess how legislation could be updated to reflect lessons learned during the pandemic. We stated the importance of having quick solutions to secure pharmaceutical products against counterfeiting. This issue is not currently addressed by the existing 2011/62/EU Falsified Medicine Directive. We believe that our digital solutions have the deployment speed required in today’s world.
Discover more about our invisible anti-counterfeiting solutions adapted for pharmaceutical products